Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2010-03-22 Board/Management Inform…
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Jakob Schlapbach (59) will resign as CFO of Cytos Biotechnology Ltd during the year 2010 and will be proposed to become a member of the board of directors
Board/Management Information Classification · 98% confidence The document is a short corporate news release dated March 22, 2010, announcing a change in senior management: the CFO, Jakob Schlapbach, will resign from his operational role and be proposed for election to the board of directors. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2010-03-22 English
Cytos Biotechnology Ltd: Dr. Thomas Hecht succeeds Dr. Francois L'Eplattenier as chairman of the Board of Directors
Board/Management Information Classification · 98% confidence The document is a short corporate news release dated March 4, 2010, announcing a change in the Board of Directors: Dr. Thomas Hecht succeeding Dr. François L’Eplattenier as chairman. This specific event—the announcement of changes in senior management or the board—directly corresponds to the definition of 'Board/Management Information' (MANG). The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Given its nature as a specific personnel announcement, MANG is the most accurate classification.
2010-03-04 English
Cytos Biotechnology announces full year 2009 financial results and major developments in 2009
Earnings Release Classification · 99% confidence The document is a short news announcement dated February 3, 2010, titled "Cytos Biotechnology announces full year 2009 financial results and major developments in 2009". It explicitly states that the complete press release containing the full year 2009 financial results can be downloaded via a provided link. According to Rule #2 (The "MENU VS MEAL" Rule), a short announcement whose primary purpose is to state that a report has been published or is available elsewhere should be classified as a Report Publication Announcement (RPA). It is not the full Annual Report (10-K) or the Interim Report (IR) itself, but the notice of their release. FY 2009
2010-02-03 English
Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb
Regulatory Filings Classification · 99% confidence The document is a press release dated November 10, 2009, titled "Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb." It details the results and conclusions from three clinical studies (Study 01, 02, and 03) regarding a therapeutic vaccine. This content is a detailed update on research and development progress, which aligns best with an Investor Presentation (IP) or a comprehensive report update, but given the format (a news release detailing clinical trial outcomes and scientific conclusions), it functions as a high-level update intended for investors and stakeholders. It is not a formal regulatory filing like a 10-K, a short earnings release (ER), or a transcript (CT). Since it provides detailed scientific and clinical findings intended to inform investors about product pipeline progress, 'Investor Presentation' (IP) is the most fitting category, as these updates often serve the same purpose as a presentation slide deck, even if delivered via a news wire (DGAP). It is a substantive update, not just an announcement of a report (RPA).
2009-11-10 English
Cytos Biotechnology AG Third Quarter Report 2009
Earnings Release Classification · 99% confidence The document is explicitly titled "Cytos Biotechnology AG Third Quarter Report 2009" and contains a "Financial summary" table comparing YTD 09/Q3 09 results against prior periods. This structure strongly indicates a comprehensive financial report for a period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). Although it mentions the full report can be downloaded, the content provided is the summary/release of the quarterly results, which is often classified as the IR document itself, rather than just an RPA, given the inclusion of key financial tables and operational highlights. It is more detailed than a typical Earnings Release (ER) which usually only provides highlights without the structured summary table. 9M 2009
2009-10-22 English
Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved
Legal Proceedings Report Classification · 99% confidence The document is dated October 15, 2009, and is titled 'Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved'. It details the results of a clinical trial update provided by Novartis regarding the drug NIC002. This content is a specific update on research and development progress, not a comprehensive annual report (10-K), a formal earnings release (ER), or a general regulatory filing (RNS). It is a corporate news announcement detailing a significant development in their product pipeline, which aligns best with a general corporate update or research news. Since there is no specific category for 'Clinical Trial Update' or 'Research News', and it is not a formal earnings release (ER) which usually focuses on financial metrics, the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general corporate announcement of material information, or potentially 'LTR' if the failure of the study is considered a significant legal/regulatory event, but RNS is the safer fallback for non-standard corporate news releases.
2009-10-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.